946 related articles for article (PubMed ID: 27666177)
1. Meta-Analysis of Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes and All-Cause Mortality Among Patients With Type 2 Diabetes Mellitus.
Tang H; Fang Z; Wang T; Cui W; Zhai S; Song Y
Am J Cardiol; 2016 Dec; 118(11):1774-1780. PubMed ID: 27666177
[TBL] [Abstract][Full Text] [Related]
2. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
Wu JH; Foote C; Blomster J; Toyama T; Perkovic V; Sundström J; Neal B
Lancet Diabetes Endocrinol; 2016 May; 4(5):411-9. PubMed ID: 27009625
[TBL] [Abstract][Full Text] [Related]
3. Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association.
Lee S
Crit Pathw Cardiol; 2017 Sep; 16(3):93-95. PubMed ID: 28742644
[TBL] [Abstract][Full Text] [Related]
4. SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials.
Tang H; Dai Q; Shi W; Zhai S; Song Y; Han J
Diabetologia; 2017 Oct; 60(10):1862-1872. PubMed ID: 28725912
[TBL] [Abstract][Full Text] [Related]
5. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
[TBL] [Abstract][Full Text] [Related]
6. Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis.
Savarese G; D'Amore C; Federici M; De Martino F; Dellegrottaglie S; Marciano C; Ferrazzano F; Losco T; Lund LH; Trimarco B; Rosano GM; Perrone-Filardi P
Int J Cardiol; 2016 Oct; 220():595-601. PubMed ID: 27390996
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.
Ghosh RK; Bandyopadhyay D; Hajra A; Biswas M; Gupta A
Int J Cardiol; 2016 Jun; 212():29-36. PubMed ID: 27017118
[TBL] [Abstract][Full Text] [Related]
8. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis.
Usman MS; Siddiqi TJ; Memon MM; Khan MS; Rawasia WF; Talha Ayub M; Sreenivasan J; Golzar Y
Eur J Prev Cardiol; 2018 Mar; 25(5):495-502. PubMed ID: 29372664
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized trials.
Saad M; Mahmoud AN; Elgendy IY; Abuzaid A; Barakat AF; Elgendy AY; Al-Ani M; Mentias A; Nairooz R; Bavry AA; Mukherjee D
Int J Cardiol; 2017 Feb; 228():352-358. PubMed ID: 27866027
[TBL] [Abstract][Full Text] [Related]
10. Impact of EMPA-REG OUTCOME
Naing S; Poliyedath A; Khandelwal S; Sigala T
Postgrad Med; 2016 Nov; 128(8):822-827. PubMed ID: 27701934
[TBL] [Abstract][Full Text] [Related]
11. Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials.
Tang H; Li D; Zhang J; Li Y; Wang T; Zhai S; Song Y
Diabetes Obes Metab; 2017 Aug; 19(8):1106-1115. PubMed ID: 28240446
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
Gebrie D; Getnet D; Manyazewal T
Sci Rep; 2021 Jan; 11(1):137. PubMed ID: 33420333
[TBL] [Abstract][Full Text] [Related]
13. Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: a systematic review and network meta-analysis of randomized controlled trials.
Kongmalai T; Hadnorntun P; Leelahavarong P; Kongmalai P; Srinonprasert V; Chirakarnjanakorn S; Chaikledkaew U; McKay G; Attia J; Thakkinstian A
Front Endocrinol (Lausanne); 2023; 14():1216160. PubMed ID: 38179304
[TBL] [Abstract][Full Text] [Related]
14. Promising cardiovascular and blood pressure effects of the SGLT2 inhibitors: a new class of antidiabetic drugs.
Chrysant SG
Drugs Today (Barc); 2017 Mar; 53(3):191-202. PubMed ID: 28447076
[TBL] [Abstract][Full Text] [Related]
15. Comparative Cardiovascular Outcomes of SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Network Meta-Analysis of Randomized Controlled Trials.
Jiang Y; Yang P; Fu L; Sun L; Shen W; Wu Q
Front Endocrinol (Lausanne); 2022; 13():802992. PubMed ID: 35370961
[TBL] [Abstract][Full Text] [Related]
16. Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials.
Tang HL; Li DD; Zhang JJ; Hsu YH; Wang TS; Zhai SD; Song YQ
Diabetes Obes Metab; 2016 Dec; 18(12):1199-1206. PubMed ID: 27407013
[TBL] [Abstract][Full Text] [Related]
17. EMPA-REG OUTCOME: The Nephrologist's Point of View.
Wanner C
Am J Med; 2017 Jun; 130(6S):S63-S72. PubMed ID: 28526179
[TBL] [Abstract][Full Text] [Related]
18. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
Rahelić D; Javor E; Lucijanić T; Skelin M
Ann Med; 2017 Feb; 49(1):51-62. PubMed ID: 27535028
[TBL] [Abstract][Full Text] [Related]
19. Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: A meta-analysis.
Zou CY; Liu XK; Sang YQ; Wang B; Liang J
Medicine (Baltimore); 2019 Dec; 98(49):e18245. PubMed ID: 31804352
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.
Reifsnider OS; Kansal AR; Gandhi PK; Cragin L; Brand SB; Pfarr E; Fahrbach K; Ustyugova A
BMJ Open Diabetes Res Care; 2021 May; 9(1):. PubMed ID: 33941549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
